The kinases Akt2, Akt3 and their myristylated variants, Myr-Akt2 and Myr-Akt3 were expressed by the RCAS vector in chicken embryo ®broblasts (CEF). Myr-Akt2 and Myr-Akt3 were strongly oncogenic, inducing multilayered foci of transformed cells. In contrast, wild-type Akt2 and Akt3 were only poorly transforming, their eciencies of focus formation were more than 100-fold lower; foci appeared later and showed less multilayering. Addition of the myristylation signal not only enhanced oncogenic potential but also increased kinase activities. Myr-Akt2 and Myr-Akt3 also induced hemangiosarcomas in the animal, whereas wild type Akt2 and Akt3 were not oncogenic in vivo. Furthermore, Akt2, driven by the lck (lymphocyte speci®c kinase) promoter in transgenic mice, induced lymphomas. The oncogenic eects of Akt2 and Akt3 described here are indistinguishable from those of Akt1. The downstream targets relevant to oncogenic transformation are therefore probably shared by the three Akt kinases. Oncogene (2001) 20, 4419 ± 4423.
Signals controlled by PI 3-kinase (PI3K) aect diverse cellular functions including response to growth factors, dierentiation, and cell survival (Alessi and Downes, 1998; Fruman et al., 1998; Shepherd et al., 1998; Wymann and Pirola, 1998) . Oncoproteins of the receptor tyrosine kinase and Src families as well as polyoma middle T antigen activate PI3K through association with the regulatory subunit of PI3K, p85, suggesting a role of PI3K in the actions of these proteins (Fukui and Hanafusa, 1989; Hu et al., 1992; Peles et al., 1992; Reith et al., 1991; Whitman et al., 1985) . The Ras oncoprotein can activate PI3K by binding to the catalytic subunit directly (RodriguezViciana et al., 1994 (RodriguezViciana et al., , 1996 . We previously showed that the oncoprotein v-P3k of the avian retroviruses ASV 16 and ASV 8905 codes for the catalytic subunit of PI3K, p110a (Chang et al., 1997; Aoki et al., 2000) .
v-P3k induces oncogenic transformation of chicken embryo ®broblasts (CEF) in culture and hemangiosarcomas in chickens (Chang et al., 1997) . The transforming activity of the P3k proteins is routed through the serine-threonine kinase Akt1 (protein kinase Ba), because dominant negative Akt1 interferes with P3k-induced transformation (Aoki et al., 1998) . The akt1 gene was originally isolated as the oncogene of the murine lymphomagenic retrovirus AKT8 (Bellacosa et al., 1991) . Cellular Akt1 binds with its plekstrin homology (PH) domain to the product of PI3K, D3-PPI, and thus is translocated to the plasma membrane. At this location, the protein kinases PDK1 and PDK2 activate Akt1 by phosphorylation of threonine 308 and serine 473 (Alessi and Cohen, 1998; Chan et al., 1999; Coer et al., 1998; Datta et al., 1999) . Constitutively activated and membrane-targeted Akt1 causes focus formation in CEF and hemangiosarcomas in chickens identical to the tumors induced by P3k (Aoki et al., 1998) . The oncogenic activity of the PI3K-Akt pathway is also manifest in human cancer. P110a (PIK110CA) is ampli®ed and overexpressed in ovarian cancers (Shayesteh et al., 1999) . Akt1 is ampli®ed in gastric cancer (Staal, 1987) . The function of a negative regulator of PI3K and Akt signals, PTEN, is lost in several types of human tumors including glioblastomas and prostate cancer. This loss of PTEN function leads to high levels of D3-PPI and activation of Akt1 (Ali et al., 1999; Cantley and Neel, 1999; Di Cristofano and Pandol®, 2000; Maehama and Dixon, 1999) .
In addition to akt1, there are two related genes in mammalian genomes, akt2 and akt3. These genes code for the Akt2 and Akt3 kinases which show a high degree of sequence homology in their catalytic and PH domains to Akt1 but diverge from Akt1 in other domains. The two regulatory phosphorylation sites that correspond to threonine 308 and serine 473 of Akt1 are conserved, and Akt2 and Akt3 also transduce PI3K signals (Altomare et al., 1998; Brodbeck et al., 1999; Liu et al., 1998; Masure et al., 1999; Meier et al., 1997; Nakatani et al., 1999a) . For both Akt2 and Akt3 there are data suggesting a role in human cancer. Akt2 is ampli®ed and overexpressed in ovarian cancer, breast cancer and pancreatic cancer and Akt3 is overexpressed in breast and prostate cancer (Bellacosa et al., 1995; Cheng et al., 1992 Cheng et al., , 1996 Miwa et al., 1996; Nakatani et al., 1999b; Ruggeri et al., 1998) . In this communication, we describe oncogenic transformation by Akt2 and Akt3 in experimental systems. The in vitro Oncogene (2001) Akt2 (of murine origin) and Akt3 (from rat) were cloned with an HA tag in the avian retroviral expression vector RCAS to yield the constructs RAkt2 and R-Akt3 (Aoki et al., 1998; Hughes et al., 1987) . Two additional constructs expressed the same tagged Akt2 or Akt3 proteins but with the myristylation signal of the c-Src kinase added at the amino termini (R-Myr-Akt2 and R-Myr-Akt3). The previously described RCAS constructs expressing Akt1 and myristylated Akt1 (R-Akt1 and R-Myr-Akt1) served as controls ( Figure 1 ) (Aoki et al., 1998) . Separate CEF cultures were transfected with these constructs, and supernatant growth medium containing infectious RCAS virus with the respective inserts was used in assays for focus formation on CEF. R-MyrAkt2 and R-Myr-Akt3 were strongly transforming, inducing foci of multilayered cells within one week as eciently as R-Myr-Akt1 ( Figure 2 , Table 1 ). In contrast, the constructs expressing the wild-type kinases, R-Akt2 and R-Akt3 were only weakly transforming, about as inecient in focus formation as non-myristylated Akt1 (Table 1) . Foci induced by R-Akt2 or R-Akt3 took about 3 weeks to develop and showed signi®cantly reduced multilayering. Rare instances of highly transformed foci in R-Akt2 or RAkt3-infected cultures probably resulted from mutations acquired during retroviral replication of the constructs. As was shown in a previous study, such mutations occur during RCAS replication and can greatly enhance focus formation mediated by a cellular insert in RCAS (Aoki et al., 2000) . Oncogenicity of non-myristylated Akt2 was observed previously by another group using NIH3T3 cells (Cheng et al., 1997) . The apparent disagreement with our results may be explained by the dierence in the host cells used in the two studies. Western blots with anti HA epitope antibody detected high levels of all Akt proteins in infected CEF (Figure 3a) . The vestigial transforming activity of R-Akt2 or R-Akt3 was therefore not caused by insucient protein expression. Kinase activities were determined by immune complex kinase assays using anti HA antibody for immunoprecipitation and Figure 1 Schematic representation of the Akt constructs used in this study. The pleckstrin homology (PH) domain, protein kinase domain, the two regulatory phosphorylation sites, the myristylation signal, and the HA epitope tag are indicated. Constructs of Akt1 and the Myr-Akt1 mutant were described previously. Akt2, and Myr-Akt2 with the myristylation signal of c-Src proteins were subcloned into the avian retroviral vector RCAS.S® via the adapter vector pBSFI (Aoki et al., 1998) . The incomplete carboxyl terminal sequences of the rat akt3 cDNA (Konishi et al., 1995) was reconstructed by PCR with a degenerate primer 5'-GCTCTCTAGATTATTC(T/C)CGTCC(A/G)CTTGCAGAGTAG-3' and the internal primer 5'-CAGGGCTCTTGATAAAG-GATCC-3' using rat brain phage cDNA library (lZAP, Stratagene) as a template (Brodbeck et al., 1999; Masure et al., 1999; Nakatani et al., 1999a) . After con®rming the sequences, the wild-type and the myristylated version of Akt3 were subcloned into RCAS.S® Crosstide, a peptide representing the Akt phosphorylation site in glycogen synthase kinase 3, as a substrate.
The myristylated Akt1 and Akt2 proteins showed signi®cantly higher kinase activity than their nonmyristylated counterparts which did not exceed background with the empty vector alone (Figure 3b ). Akt3 was unusual because of its high kinase activity (Nakatani et al., 1999a) . Even the non-myristylated form of Akt3 exceeded the kinase activities of myristylated Akt1 or myristylated Akt2, and that indigenous activity of Akt3 was further elevated by myristylation. Akt3 may therefore possess stronger intrinsic kinase activity either on all or merely on selected substrates. Substrate preference between Akt kinases has been observed. In the present study, Akt2 Fertilized chicken eggs were obtained from SPAFAS. Primary CEF cultures, focus assays and DNA transfections using DMSOpolybrene method were described previously (Aoki et al., 1998) . Assay plates were evaluated after staining with crystal violet. Tests for tumor formation in young chickens followed published procedures (Aoki et al., 1998) . Cell culture supernatants of transfected, RCAS construct-releasing CEF were serially diluted and added to fresh secondary cultures of CEF in 35 mm plates. The cultures were overlaid with nutrient agar for 3 weeks and stained with crystal violet (Aoki et al., 2000) . See Table 1 (Aoki et al., 1998) . Lysates containing 40 mg of protein were separated by SDS ± PAGE and transferred to an Immobilon-P membrane (Millipore). The membrane was probed with anti HA monoclonal antibody HA-11 (BabCo) followed by horseradish peroxidase conjugated secondary antibody (Amersham). Akt proteins were visualized by incubation with a chemiluminescent substrate (Renaissance Plus, NEN). (b) Immune complex kinase assay. The Akt proteins were immunoprecipitated from the lysates containing 80 mg of protein with anti HA antibody and protein G sepharose beads (Pharmacia). Immune complex kinase assay was performed according to the protocol of Upstate Biotechnology with the Crosstide peptide as a substrate proved inecient on histone H2B which is a good substrate for Akt1, whereas both Akt2 and Akt1 eciently phosphorylated myelin basic protein (data not shown). As Akt3 is poorly transforming, high kinase activity cannot be the sole determinant of oncogenicity. This conclusion is also supported by previous observations on an Akt1 mutant in which the activation phosphorylation sites threonine 308 and serine 473 were replaced by aspartic acid (Akt1-T308DS473D). This mutant showed constitutive kinase activity equivalent to that of Myr-Akt1, yet it failed to induce oncogenic transformation (Aoki et al., 1998) . The myristylated Akt2 or myristylated Akt3 proteins were also oncogenic in the animal. Injection of R-MyrAkt2-or R-Myr-Akt3-producing CEF into the wing web of young chickens caused aggressively growing hemangiosarcomas in all inoculated birds within one week. The histopathology of these tumors was identical to the hemangiosarcomas induced by R-Myr-Akt1 or myristylated p110 of PI3K. The RCAS constructs expressing the non-myristylated forms of the Akt kinases did not induce tumors in vivo. These in vitro and in vivo observations suggest that besides kinase activity, constitutive membrane localization is a prerequisite for the oncogenicity of Akt kinases.
To test the oncogenic potential of Myr-Akt2 in mammals, we generated Myr-Akt2 transgenic mice under the control of the lck gene promoter (Figure 4a ). The lck promoter was chosen because it has been used to direct transgene expression in T lymphocytes, and AKT8 virus containing the akt1 oncogene speci®cally induces thymomas in mice. We followed the survival of these mice for 600 days. Twenty-three of the thirtythree transgenics died during this period, 18 with a diagnosis of lymphoma and ®ve of undetermined causes. In the same period, six of the 30 controls died; two had splenomegaly, the other four showed no evidence of neoplastic disease. Expression of the MyrAkt2 transgene in thymoma cells was con®rmed by Western blot using anti Akt2 antibody (Figure 4b ).
Akt1, Akt2 and Akt3 are functionally similar in their eects on cellular growth; membrane-targeted versions of these proteins are oncogenic in vitro and in vivo. All three induce hemangiosarcomas in chickens; Akt1 and Akt2 are also lymphomagenic in mice. This dierence in tumor spectrum between avian and mammalian species may be more apparent than real: Injected chickens develop hemangiosarcomas so rapidly that the typically slower arising lymphomas would be missed, and the murine injections are biased toward expression in lymphocytes by the lck promoter and probably also by the LTR of the AKT8 retrovirus.
The oncogenic potential of Akt2 and of Akt3 uncovered in this study suggests that the frequent ampli®cation and upregulation of these kinases in human tumors may play an important role in the induction and maintenance of the neoplastic phenotype. However, since overexpression of any wild-type Akt protein is insucient to cause transformation, other genetic changes aecting PI3K signaling probably occur in these tumors. Candidates for such mutations are a loss of function in the tumor suppressor PTEN or mutations in one of the downstream signaling components that are responsive to Akt. An elevated basal activity of Akt3 kinase was found in a prostate cancer cell line PC-3, which over-expresses Akt3 and lacks PTEN (Nakatani et al., 1999b) .
The Akt kinases phosphorylate directly or indirectly diverse substrates. Examples are the Fox-O transcription factors FKHR, FKHR-L1 and AFX, nitric oxide synthase, the eukaryotic initiation factor 4E-binding protein (4E-BP1), the pro-apoptotic protein BAD, the kinases IKK, mTOR, GSK-3b and p70S6k (IkB kinase, mammalian target of rapamycin, glycogen synthase kinase 3b, p70 S6 kinase (Alessi and Cohen, 1998; Chan et al., 1999; Coer et al., 1998; Datta et al., 1999) . Substrate selection may be aected by cellular localization (Dufner et al., 1999) . In CEF, myristylated Akt1 but not the nonmyristylated yet kinase-active mutant Akt1-T308DS473D induces phosphorylation of p70 S6k and 4E-BP1 (Aoki et al., 2001) . Since the Akt kinases are indistinguishable in their oncogenic action in vitro and in vivo, it is likely that they share essential oncogenic targets which now must be identi®ed in order to understand the mechanisms of Akt and of PI3K-induced transformation. Phosphorylation of a set of these Akt targets will be both necessary and sucient for oncogenic transformation. The myristylation signal and HA epitope tag are indicated. Myr-Akt2 was subcloned from pcDNA3-MyrAkt2 into HindIII ± XbaI sites of CMV5 plasmid, and then the BglII ± BamHI fragment of Myr-Akt2 was transferred to pLCK vector digested with BamHI (Abraham et al., 1991; Andersson et al., 1989) . The pLCK/Myr-Akt2 construct was sequenced to ensure proper orientation of the insert. The insert containing the lck (lymphocyte speci®c kinase) promoter, Myr-Akt2, and the human growth hormone gene polyadenylation signal was isolated from the vector using NotI, puri®ed, and then microinjected into C57Bl/6J X C3H/HeJ F2 mouse oocytes as described previously (Ceci et al., 1989 (Ceci et al., , 1991 Osborn et al., 1987) . To identify transgenic founder mice, genomic DNA was isolated from the tails of live-born weanling mice (Siracusa et al., 1987) , DNA was digested to completion with SacI and analysed by Southern blotting using a 7700 bp probe obtained by KprI ± SacI digestion of pCMV/Akt2. (b) Western blot analysis of the Myr-Akt2 protein in a Myr-Akt2 transgenic mouse and its non transgenic littermate
